ALIM - Alimera Sciences, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
0.8847
-0.0254 (-2.79%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close0.9101
Open0.9200
Bid0.8800 x 800
Ask0.9250 x 21500
Day's Range0.8600 - 0.9750
52 Week Range0.7200 - 1.2100
Volume514,428
Avg. Volume108,275
Market Cap62.786M
Beta (3Y Monthly)2.20
PE Ratio (TTM)3.55
EPS (TTM)0.2490
Earnings DateApr 30, 2019 - May 6, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.81
Trade prices are not sourced from all markets
  • ACCESSWIRE8 hours ago

    Alimera Sciences Announces Multiple Posters and a Podium Presentation of Clinical Data for ILUVIEN(R) to be Presented at the Association for Research and Vision in Ophthalmology (ARVO) Annual Meeting

    ATLANTA, GA / ACCESSWIRE / April 23, 2019 / Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, announces that ...

  • ACCESSWIRE19 days ago

    Alimera Sciences Announces Expansion of Leadership Team with Appointment of Samer Kaba, MD as Chief Medical Officer

    ATLANTA, GA / ACCESSWIRE / April 4, 2019 / Alimera Sciences, Inc. (ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced an expansion of its leadership team with the appointment of Samer Kaba, MD as Chief Medical Officer, effective April 4, 2019. "I am very pleased that Samer will be joining us in this new position as he will bring both a physician's perspective and medical leadership to generate more data on the uniqueness of ILUVIEN®'s ability to help patients maintain vision longer with fewer injections," said Rick Eiswirth, President and Chief Executive Officer. Dr. Kaba was appointed Chief Medical Officer, a new position at Alimera Sciences, as of April 3, 2019 and will be a member of the Company's Executive Management Team.

  • ACCESSWIRE29 days ago

    Alimera Sciences Announces Approval Received in the Mutual Recognition Procedure for New Indication for ILUVIEN(R) in Europe

    ATLANTA, GA / ACCESSWIRE / March 25, 2019 / Alimera Sciences, Inc. (ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced a positive outcome for a new indication for ILUVIEN in Europe. Alimera received the Final Variation Assessment Report (FVAR) for ILUVIEN from the Medicines and Healthcare products Regulatory Agency of the United Kingdom (MHRA) based on Alimera's submission to the MHRA through the Mutual Recognition Procedure.

  • ACCESSWIRElast month

    Alimera Sciences Announces Approval for ILUVIEN (R) in Kuwait

    ATLANTA, GA / ACCESSWIRE / March 21, 2019 / Alimera Sciences, Inc. (ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that ILUVIEN has fulfilled all requirements for registration according to the Pharmaceutical & Herbal Medicines Registration & Control Administration, Ministry of Health, Kuwait. Alimera's partner, MEAgate International FZLLC (MEAgate), headquartered in Dubai, will be responsible for obtaining pricing and launching ILUVIEN in Kuwait.

  • ACCESSWIRE2 months ago

    Alimera Sciences Announces the Reimbursement of ILUVIEN(R) in France

    ATLANTA, GA / ACCESSWIRE / March 6, 2019 / Alimera Sciences, Inc. (ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that its subsidiary, Alimera Sciences Limited, received a positive resolution for the pricing and reimbursement approval for ILUVIEN® from Comité Economique des Produits de Santé (CEPS). This means that in France, ILUVIEN will be fully reimbursed for use in line with the European label indication. This approval was sought and secured by Alimera's distributor partner in France, Horus Pharma S.A.S. (Horus).

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of ALIM earnings conference call or presentation 19-Feb-19 2:00pm GMT

    Q4 2018 Alimera Sciences Inc Earnings Call

  • Will Alimera Sciences (ALIM) Report Negative Q4 Earnings? What You Should Know
    Zacks2 months ago

    Will Alimera Sciences (ALIM) Report Negative Q4 Earnings? What You Should Know

    Alimera Sciences (ALIM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • ACCESSWIRE2 months ago

    Alimera Sciences, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / February 19, 2019 / Alimera Sciences, Inc. (NASDAQ: ALIM ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on February 19, 2019 at ...

  • ACCESSWIRE2 months ago

    Alimera Sciences Reports Record Fourth Quarter and 2018 Results

    Fourth Quarter 2018 Highlights Fourth quarter 2018 consolidated net revenue up 66% International segment revenue increased 138% over the prior year period Net Loss of $1.2 million vs. Net Loss of $7.2 ...

  • ACCESSWIRE3 months ago

    Alimera Sciences Announces Approval for ILUVIEN(R) in Lebanon

    ATLANTA, GA / ACCESSWIRE / February 5, 2019 / Alimera Sciences, Inc. (ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that product registration has been received for ILUVIEN from the Ministry of Health in Lebanon, through its partner MEAgate International FZLLC, headquartered in Dubai. ILUVIEN is a sustained release intravitreal implant indicated for the treatment of diabetic macular edema in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure.

  • ACCESSWIRE3 months ago

    Alimera Sciences to Report Fourth Quarter and Full Year 2018 Results on February 18, 2019

    ATLANTA, GA / ACCESSWIRE / February 4, 2019 / Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced ...

  • ACCESSWIRE3 months ago

    Alimera Sciences Affirms Record 2018 Revenues

    ATLANTA, GA / ACCESSWIRE / January 7, 2019 / Alimera Sciences, Inc. (ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today affirmed that it expects record annual 2018 and fourth quarter 2018 revenues, with 2018 GAAP net revenue in excess of $45 million and fourth quarter 2018 GAAP net revenue in excess of $13 million. Additionally, Alimera anticipates reporting positive adjusted EBITDA for the three months ended December 31, 2018. In making this announcement, Alimera confirmed the previous estimates in its Current Report on Form 8-K dated December 4, 2018.

  • What Type Of Shareholder Owns Alimera Sciences, Inc.’s (NASDAQ:ALIM)?
    Simply Wall St.4 months ago

    What Type Of Shareholder Owns Alimera Sciences, Inc.’s (NASDAQ:ALIM)?

    A look at the shareholders of Alimera Sciences, Inc. (NASDAQ:ALIM) can tell us which group is most powerful. Institutions often own shares in more established companies, while it's not unusual Read More...

  • ACCESSWIRE4 months ago

    Alimera Sciences Announces Pricing Approval For ILUVIEN(R) in the U.A.E.

    ATLANTA, GA / ACCESSWIRE / December 17, 2018 / Alimera Sciences, Inc. (ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that pricing approval had been received for ILUVIEN from the United Arab Emirates Ministry of Health & Prevention, effective January 24, 2019 through its partner MEAgate International FZLLC, headquartered in Dubai. "Diabetes is an important disorder in our region with a high prevalence and lower levels of control by patients of their disease," said Dr. Ahmed ElBarky, Assistant Professor of Opthalmology, Benha University, Egypt, consultant vitreoretinal surgeon, Sheikh Khalifa Medical Center in Abu Dhabi. "We are glad that ILUVIEN, which represents the latest medical introduction and innovation in the treatment of DME, is now available for our patients.

  • ACCESSWIRE5 months ago

    Alimera Sciences Appoints Rick Eiswirth as Chief Executive Officer

    ATLANTA, GA / ACCESSWIRE / November 29, 2018 / Alimera Sciences, Inc. (ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that the company's Board of Directors has appointed Rick Eiswirth as Chief Executive Officer, effective January 2, 2019. Mr. Eiswirth will assume day-to-day leadership of the company, retain his title of President, and join Alimera's Board of Directors.

  • ACCESSWIRE5 months ago

    Alimera Sciences Announces Canadian Regulatory Approval for ILUVIEN(R)

    ATLANTA, GA / ACCESSWIRE / November 26, 2018 / Alimera Sciences, Inc. (ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that Health Canada has approved ILUVIEN® for the treatment of diabetic macular edema (DME). ILUVIEN is a fluocinolone acetonide sustained release intravitreal implant approved in the U.S. to treat DME in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure. Alimera signed an exclusive Canadian agreement for ILUVIEN with Knight Therapeutics, Inc. ("Knight") in July 2015.

  • GlobeNewswire5 months ago

    Consolidated Research: 2018 Summary Expectations for Texas Instruments, Sino-Global Shipping America, Alimera Sciences, Sypris Solutions, JetPay, and Performant Financial — Fundamental Analysis, Key Performance Indications

    NEW YORK, Nov. 21, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Thomson Reuters StreetEvents5 months ago

    Edited Transcript of ALIM earnings conference call or presentation 6-Nov-18 2:00pm GMT

    Q3 2018 Alimera Sciences Inc Earnings Call

  • ACCESSWIRE5 months ago

    Alimera Sciences to Present at Upcoming Investor Conferences

    ATLANTA, GA / ACCESSWIRE / November 9, 2018 / Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced ...

  • Alimera Sciences (ALIM) Reports Q3 Loss, Tops Revenue Estimates
    Zacks6 months ago

    Alimera Sciences (ALIM) Reports Q3 Loss, Tops Revenue Estimates

    Alimera Sciences (ALIM) delivered earnings and revenue surprises of 16.67% and 0.15%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press6 months ago

    Alimera Sciences: 3Q Earnings Snapshot

    The Alpharetta, Georgia-based company said it had a loss of 39 cents per share. Losses, adjusted for non-recurring gains, were 5 cents per share. The results beat Wall Street expectations. The average ...

  • ACCESSWIRE6 months ago

    Alimera Sciences Reports Third Quarter 2018 Results

    Record Net Revenue of $11.1 Million in Q3 2018; U.S. Net Revenue up 20% Record U.S. End User Demand in Q3 2018 Net Loss and Adjusted EBITDA Loss Continue to Improve ATLANTA, GA / ACCESSWIRE / November ...

  • ACCESSWIRE6 months ago

    Alimera Sciences to Report Third Quarter 2018 Results November 5, 2018

    ATLANTA, GA / ACCESSWIRE / October 23, 2018 / Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced ...

  • ACCESSWIRE6 months ago

    Alimera Sciences Announces Six ILUVIEN(R) Posters to be Presented at 2018 American Academy of Ophthalmology

    ATLANTA, GA / ACCESSWIRE / October 22, 2018 / Alimera Sciences, Inc. (ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that six posters on ILUVIEN® will be available during the 2018 Annual Meeting of the American Academy of Ophthalmology (AAO) at McCormick Place in Chicago, October 26-30. In addition, Alimera is sponsoring an educational event at the meeting. "We continue to generate exciting data on ILUVIEN, including two posters from our ongoing prospective PALADIN study," said Dan Myers, CEO of Alimera.

  • Eye implant is helping treat vision loss in diabetics
    Yahoo Finance Video3 months ago

    Eye implant is helping treat vision loss in diabetics

    Alimera Sciences, a biotech company specializing in eye diseases, is changing the way vision loss is treated for diabetics with an eye implant smaller than a grain of rice. Yahoo Finance’s Alexis Christoforous speaks to Rick Eiswirth, the CEO of Alimera Sciences, about the treatment.